GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a health official said on Friday during a press briefing.

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance ... saw sales tumble 72%, its influenza vaccine saw sales slump 24% and its shingles vaccine saw sales weaken by 7%.

Notably, GSK points to the rapid creation of an mRNA vaccine candidate during the 2013 influenza outbreak in China, setting a record for vaccine development time. The scientific journal Nature hig ...

Sales of the influenza vaccine, Fluarix, were down 22%. Sales of Established vaccines improved 10%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine co-developed ...

and inactivated trivalent influenza vaccine (TIV; Fluarix™, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to ...

British Drugmaker GSK Moves MRNA Flu Vaccine to Late-stage Trials British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of ...

British drugmaker GSK on Wednesday bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials and extending the German ...

I'm pleased to report that despite some challenges, this has been a positive quarter for GSK, and we're delivering ... headline data from our mRNA influenza vaccine candidate, demonstrating ...